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ABSTRACT
Purpose To study the effect of oxidation on the structure of
recombinant human interferon beta-1a (rhIFNβ-1a) and its
immunogenicity in wild-type and immune-tolerant transgenic mice.
Methods Untreated rhIFNβ-1a was degraded by metal-
catalyzed oxidation, H2O2-mediated oxidation, and guanidine-
mediated unfolding/refolding. Four rhIFNβ-1a preparations
with different levels of oxidation and aggregation were injected
intraperitoneally in mice 15× during 3 weeks. Both binding
and neutralizing antibodies were measured.
Results All rhIFNβ-1a preparations contained substantial
amounts of aggregates. Metal-catalyzed oxidized rhIFNβ-1a
contained high levels of covalent aggregates as compared with
untreated rhIFNβ-1a. H2O2-treated rhIFNβ-1a showed an
increase in oligomer and unrecovered protein content by HP-
SEC; RP-HPLC revealed protein oxidation. Guanidine-treated
rhIFNβ-1a mostly consisted of dimers and oligomers and
some non-covalent aggregates smaller in size than those in
untreated rhIFNβ-1a. All degraded samples showed alterations
in tertiary protein structure. Wild-type mice showed equally
high antibody responses against all preparations. Transgenic
mice were discriminative, showing elevated antibody
responses against both metal-catalyzed oxidized and H2O2-
treated rhIFNβ-1a as compared to untreated and guanidine-
treated rhIFNβ-1a.
Conclusions Oxidation-mediated aggregation increased the
immunogenicity of rhIFNβ-1a in transgenic mice, whereas
aggregated preparations devoid of measurable oxidation levels
were hardly immunogenic.
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rhIFNβ-1b recombinant human interferon beta-1b
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INTRODUCTION
Patients treated with therapeutic proteins frequently suffer
from side effects or ineffective treatment caused by adverse
immune responses against the drug (1). Multiple sclerosis
patients treated with recombinant human interferon beta
(rhIFNβ) may experience reduced efficacy of the drug
during chronic treatment (2). The therapeutic effect of
rhIFNβ is influenced by the formation of binding antibodies
(BABs) and neutralizing antibodies (NABs). High levels of
NABs, often preceded by BABs, block the biological activity
of the protein. Molecular characteristics have been found to
play a key role in the unwanted immunogenicity of protein
pharmaceuticals (3,4).
Endogenous human interferon beta (hIFNβ) is a cytokine
produced by macrophages and epithelial and fibroblast
cells. The protein binds to the cell receptor as a dimer and
has antiviral, antiproliferative and immunomodulatory
properties (5). Recombinant human interferon beta-1a
(rhIFNβ-1a) is produced in CHO cells, and its primary
sequence is identical to that of natural hIFNβ. The
therapeutic protein has a molecular weight of approxi-
mately 22.5 kDa, including 166 amino acids and a single N-
linked carbohydrate chain. The protein structure comprises
five α-helices, one intramolecular disulfide bond, and a free
cysteine near the N-terminus that might play a role in the
formation of protein aggregates through inter- and intra-
molecular disulfide scrambling (6,7). The carbohydrate
chain was suggested to protect an unusually large hydro-
phobic region of the protein, as de-glycosylation of rhIFNβ-
1a renders the protein poorly soluble and prone to ag-
gregation (8).
The presence of aggregates not only affects the biological
activity of rhIFNβ but can also enhance its immunogenicity
(9). This is illustrated by the relatively low bioactivity and
high clinical immunogenicity of the commercial product
Betaferon®. The active substance of Betaferon® is rhIFNβ-
1b, a non-glycosylated form of rhIFNβ that is produced in
E. coli and forms up to 60% large, soluble and non-covalent
aggregates (8). Large, non-covalent aggregates were also
detected in solutions of glycosylated rhIFNβ-1a in a buffer
of sodium phosphate and sodium chloride at pH 7.2 (10).
Removing the aggregates and formulating the protein in a
sodium acetate buffer at pH 4.8 with polysorbate 20 and
arginine significantly reduced the immunogenicity of the
protein in transgenic mice immune tolerant for human
interferon beta. Incubation of rhIFNβ-1a at low pH and
high salt induced the formation of covalent aggregates, but
did not enhance its immunogenicity (10). So far, studies
with transgenic immune-tolerant mice have shown that
aggregates potentially increase the immunogenicity of
rhIFNβ; however, not all aggregates are equally immuno-
genic (10–12).
The immunogenicity of a therapeutic protein can also be
enhanced by chemical modification, such as hydrolysis,
deamidation, or oxidation (13). Oxidation is one of the
major degradation pathways for proteins (14,15). Those
amino acids containing a sulfur atom (Cys and Met) or an
aromatic ring (His, Trp, Tyr and Phe) are most susceptible
and involved in numerous types of oxidative mechanisms (for
an overview, see reference (16)). Oxidation of therapeutic
proteins occurs during formulation, fill-finish, freeze-drying
or storage, for example, due to exposure to intense light,
trace amounts of metal ions or peroxide impurities in, e.g.,
polysorbate excipients (14,15,17). Lam et al. described the
oxidation of a recombinant humanized monoclonal antibody
in liquid formulations when exposed to intense light and
elevated temperatures (30°C and 40°C) (17). Also, corrosion
of stainless steel containers by chloride ions in the formula-
tion buffer at low pH can generate iron ions that catalyze
methionine oxidation (17).
Oxidation of biological proteins can have various
consequences, such as inhibition of enzymatic and binding
activities, increased or decreased uptake by cells, increased
susceptibility to proteolysis and aggregation, and altered
immunogenicity (16). UV light at 302 nm induced
oxidation of Trp residues and subsequent aggregation of
the model therapeutic protein type I soluble tumor necrosis
factor receptor (18). Peroxodisulfate-mediated oxidation of
recombinant human interleukin-2 induced a change in the
secondary structure of the protein, as observed by far-UV
circular dichroism (W. Jiskoot, unpublished results). Metal-
catalyzed oxidation of human relaxin resulted in alter-
ations in secondary and tertiary structure and increased
exposure of hydrophobic surface, leading to aggregation
and precipitation (19). Hermeling et al. demonstrated the
formation of highly immunogenic aggregates upon oxida-
tion of recombinant human interferon alpha-2b (rhIFNα-
2b) via catalysis with copper ions (20). A combination of
ascorbic acid and transition metal ions (Fe3+ or Cu2+) is
often used as a model system to study the effect of site-
specific metal-catalyzed oxidation. The metal ions bind to
specific chelating or ionic spots of the protein, forming
active oxygen intermediates such as H2O2, O2· and HO·,
which subsequently react with one of the amino acid side
chains in their immediate proximity (16). Protein damage
can also occur more distant from the initial oxidation event,
e.g., when oxidized Cys residues catalyze the oxidation of
other amino acids (21).
Here, we present data on the effect of two different
oxidation pathways on the structure and aggregation state of
rhIFNβ-1a and its immunogenicity in wild-type and trans-
genic immune-tolerant mice. For comparison, two rhIFNβ-1a
preparations containing aggregates but no measurable
amounts of oxidation products were also tested. The results
strongly suggest that the combination of oxidation and
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Recombinant hIFNβ-1a was supplied by Biogen Idec Inc.
(Cambridge, MA, USA) as a 0.26 mg/ml solution in
20 mM sodium acetate buffer and 154 mM arginine at pH
4.8. Before use, this solution was dialyzed with a 3.5 kDa
MWCO Slide-A-Lyzer Cassette (Perbio Science, Etten-Leur,
the Netherlands) against 100 mM sodium phosphate buffer
and 200mM sodium chloride at pH 7.2 (PBS). This solution is
further referred to as untreated rhIFNβ-1a.
Three different degradation products were prepared
from untreated rhIFNβ-1a. To obtain metal-catalyzed
oxidized rhIFNβ-1a, untreated rhIFNβ-1a, diluted to
200 μg/ml with PBS, was incubated with 4 mM ascorbic
acid and 0.04 mM CuCl2 for 3 h at room temperature
according to Li et al. (19). The oxidation reaction was
stopped by adding 100 mM EDTA to a final concentration
of 1 mM. Hydrogen peroxide (H2O2)-mediated oxidation
was achieved by incubation of 200 μg/ml untreated
rhIFNβ-1a with 0.005% (v/v) H2O2 for 20 h at 37°C
according to the European Pharmacopeia (22). The
reaction was stopped by the addition of 12 mg methionine
per ml followed by incubation at room temperature for 1 h.
Finally, rhIFNβ-1a was unfolded by overnight dialysis of
200 μg/ml untreated rhIFNβ-1a against 6 M guanidine
hydrochloride at 4°C. After degradation, the oxidized and
guanidine-treated samples were dialyzed extensively against
PBS. All rhIFNβ-1a samples were stored at −80°C.
Physicochemical Characterization
Visual Inspection
RhIFNβ-1a samples (100 μg/ml) were inspected visually at
the lab bench with the sample buffer as a reference.
Dynamic Light Scattering (DLS)
The average diameter (Z-ave) of particles in rhIFNβ-1a
samples and their polydispersity index (PDI) were assessed
with dynamic light scattering (DLS). Samples were diluted
with the sample buffer to a concentration of 100 μg/ml
protein and analyzed using a Malvern Zetasizer Nano ZS
apparatus equipped with a red laser (λ=633 nm), a detector
at 173º, and Dispersion Technology Software version 4.20.
Samples were measured at 25°C in the presence or absence
of 0.01% (w/v) sodium dodecyl sulfate (SDS).
UV Spectroscopy
UV absorbance was measured at 25°C in quartz cuvettes
with a path length of 1 cm with an Agilent 8453 UV/VIS
spectrophotometer and an Agilent 89090 A controller.
Samples were diluted with the sample buffer to a
concentration of 100 μg/ml rhIFNβ-1a and measured in
the presence or absence of 0.01% (w/v) SDS. Zero-order
spectra were recorded at wavelengths of 190 to 1100 nm.
Second-derivative UV spectroscopy enabled us to monitor
changes in the microenvironment of aromatic amino acid
residues without interference of light scattering (23,24). UV
spectra (λ=240–360 nm) were recorded with an integration
time of 15 s and a 1-nm interval. Second-derivative spectra
were calculated and interpolated with 99 data points using
the Agilent UV-Visible ChemStation Software.
High Performance Size Exclusion Chromatography (HP-SEC)
RhIFNβ-1a preparations (100 μl, 200 μg/ml) were charac-
terized with a TSKgel Super SW2000 column and Super
SW guard column (Sigma Aldrich). A Shimadzu SPD-6AV
UV detector recorded the chromatograms at a wavelength
of 280 nm. A flow rate of 0.35 ml/min was applied using a
Waters 515 HPLC pump and 717 Plus autosampler. The
mobile phase consisted of 200 mM sodium chloride, 0.05%
(w/v) sodium azide and 0.1% (w/v) SDS in a buffer of
100 mM sodium phosphate (pH 7.2), which was filtered
through a 0.2-μm filter prior to use.
Reversed-Phase High Performance Liquid Chromatography
(RP-HPLC)
A Jupiter 300 (5 μm, 250*4.6 mm) C4 column was used in
combination with a SecurityGuard (4*3 mm) C4 guard
column (Phenomenex, Amstelveen, the Netherlands). The
mobile phase was delivered at a flow rate of 1 ml/min by a
Waters 600 controller coupled to a Waters 717 Plus
autosampler, and chromatograms were recorded with a
UV detector (Waters 2487) at a wavelength of 214 nm. The
eluents were 10% acetonitrile with 0.1% trifluoroacetic
acid (TFA) and 100% acetonitrile with 0.1% TFA. After
application of the sample (20 μl, 200 μg/ml), an elution
gradient was applied according to Geigert et al. (25).
Immunogenicity Study
Mouse Breeding
Human IFNβ transgenic immune-tolerant C57Bl/6 mice,
previously developed by Hermeling et al. (11), were bred at
the Central Laboratory Animal Institute (Utrecht Univer-
sity, the Netherlands). Transgenic mice were crossed with
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wild-type C57Bl/6 mice (Janvier, Bioservices, Uden, the
Netherlands) to maintain the strain. Presence of the hIFNβ
gene in the offspring was verified by PCR using chromo-
somal DNA obtained from ear tissue. Transgenic C57Bl/6
offspring were crossed with wild-type FVB/N mice (Janvier).
Their C57Bl/6 x FVB/N hybrid offspring were genotyped,
and both transgenic and non-transgenic littermates (12) were
used in the animal experiment.
Animal Experiment
Food (Hope Farms, Woerden, the Netherlands) and water
(acidified) were provided ad libitum, and the animal study
was approved by the Institutional Ethical Committee.
Blood was collected submandibularly from 40 wild-type
and 40 transgenic mice before treatment was started
(11,12). Ten mice per group were injected intraperitoneally
(i.p.) with 5 μg of untreated, metal-catalyzed oxidized,
H2O2-treated or guanidine-treated rhIFNβ-1a at day 0–4,
day 7–11, and day 14–18. At days 7 and 14, blood was
drawn submandibularly just before injection with rhIFNβ-1a,
and at day 21 all mice were sacrificed by bleeding through
cardiac puncture under isoflurane anesthesia. Lithium
heparin gel tubes were used to collect blood and obtain
plasma samples by centrifugation (3000 g; 10 min). Plasma
was stored at −80°C until analysis.
Binding Antibody Assay
The plasma samples were analyzed by direct ELISA
according to the protocol described by Hermeling et al.
(11). Plates were coated with untreated rhIFNβ-1a to
measure the levels of BABs that cross-react with the
untreated protein. Absorbance values were measured at a
wavelength of 405 nm and a reference wavelength of
490 nm using a BioTek EL808 microplate reader (Beun de
Ronde, Abcoude, the Netherlands). The 100-fold diluted
plasma samples were screened and defined positive if the
background-corrected absorbance values were 10 times
higher than that of the pre-treatment plasma. Titers of anti-
hIFNβ IgG in positive plasma were determined by plotting
the absorbance values of a serial dilution against log
dilution. A standard anti-hIFNβ plasma with an average
log titer value of 3.41±0.10 (SD; n=30) was added to each
plate. Plots were fitted to a sigmoidal dose-response curve
with GraphPad Prism software version 4.00 for Windows
(San Diego CA, USA). The titer of the plasma was
determined from the reciprocal of the dilution of the
EC50 value. A titer of 10 was given to non-responders, and
statistical analyses were performed with a Kruskal-Wallis
non-parametric one-way ANOVA and Dunn’s multiple
comparison test.
Neutralizing Antibody Assay
A bioassay that was based on inhibition of induction of
myxovirus resistance protein A (MxA) gene expression in an
A549 cell line (26) was used to measure NAB levels at day
21 in plasma. MxA and a control housekeeping gene-
derived mRNA (eukaryotic 18S rRNA) were detected with
a real-time RT-PCR multiplex assay. Neutralizing activity
was measured in ten-fold reduction units per ml (TRU/ml).
Plasma samples were considered NAB-negative if neutral-
izing activity was below 130 TRU/ml (10,26).
RESULTS
Physicochemical Characteristics of rhIFNβ-1a
Structural Variants
Visual Inspection
A homogeneous white haze was visible in all protein
preparations with an intensity that was highest for metal-
catalyzed oxidized and lowest for untreated rhIFNβ-1a,
with the H2O2-treated product being slightly more turbid
than the guanidine-treated product. No distinct visible
particles could be discerned.
Dynamic Light Scattering (DLS)
The size distributions of the samples measured by dynamic
light scattering (DLS) varied considerably between repeated
runs; therefore, average diameters (Z-ave) and polydisper-
sity indices (PDI) are presented (Table I). In line with
previous results (10), untreated rhIFNβ-1a showed high
values for both Z-ave (3.2 μm) and PDI (1.0), indicating the
presence of large aggregates heterogeneous in size. The
aggregates in untreated rhIFNβ-1a disassembled upon
addition of 0.01% (w/v) SDS, however, not completely
given the observed Z-ave of 210 nm and the theoretical
diameter of approximately 3 nm for monomeric rhIFNβ-1a
according to its crystal structure (6). H2O2-oxidized
rhIFNβ-1a had similar Z-ave and PDI as untreated
rhIFNβ-1a, both in absence and presence of SDS. The Z-
ave of metal-catalyzed oxidized rhIFNβ-1a in absence of
SDS was slightly smaller and in presence of SDS slightly
larger than those of untreated and H2O2-oxidized rhIFNβ-
1a. This suggests that the aggregates in the metal-catalyzed
oxidized preparation differed from those in the untreated
product. Guanidine-treated rhIFNβ-1a demonstrated a
remarkably lower Z-ave and PDI than untreated rhIFNβ-
1a (without SDS), which can be explained by dissociation of
some of the aggregates upon unfolding with guanidine. The
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decrease in Z-ave after the addition of SDS indicates that
part of the (larger) aggregates in the guanidine-treated
preparation was non-covalently bound.
Zero-Order UV Spectroscopy
In addition to the absorbance around 280 nm caused by
aromatic amino acid residues and disulfide bonds, the zero-
order UV spectra of proteins can show wavelength-
dependent apparent absorbance due to aggregates in the
solution that scatter light (23). The light scattering intensity
depends on aggregate size, shape, and amount, and is more
pronounced at lower wavelengths. A decrease in optical
density (OD) at 350 nm in untreated rhIFNβ-1a from 0.13
to 0.01 after addition of 0.01% (w/v) SDS indicates the
presence of non-covalently bound aggregates (Table I). In
absence of SDS, metal-catalyzed oxidized and H2O2- and
guanidine-treated rhIFNβ-1a showed decreased OD280/
OD260 ratios and increased OD350 values as compared
with untreated rhIFNβ-1a, indicating extensive aggregation
(Fig. 1a). The UV spectrum of metal-catalyzed oxidized
rhIFNβ-1a was least affected by the addition of SDS,
indicating the presence of a significant amount of covalent
aggregates in this preparation (Fig. 1c).
Second-Derivative UV Spectroscopy
Second-derivative UV spectra of proteins provide valuable
information on chromophores distributed throughout the
protein molecule and are sensitive to a wide variety of
chemical and structural changes (23,24). Peaks in the
wavelength region between 240 and 270 nm can be
attributed mainly to phenylalanine, while tyrosine and
tryptophan are responsible for peaks between 275 and
310 nm, with the region between 295 and 310 nm being
affected mostly by tryptophan (24). Without SDS, the
second-derivative UV spectra of the degraded samples
clearly differed from that of untreated rhIFNβ-1a, partic-
ularly in the Tyr and Trp region (Fig. 1b). The microen-
vironment of the phenylalanines in guanidine-treated
rhIFNβ-1a also differed from that in untreated rhIFNβ-
1a. The complete spectrum of guanidine-treated rhIFNβ-1a
showed a red shift of 0.5–0.7 nm as compared with
untreated rhIFNβ-1a, indicating a more hydrophobic
environment of the chromophores (23). The addition of
0.01% (w/v) SDS resulted in nearly overlaying second-
derivative UV spectra of untreated and H2O2- and
guanidine-treated rhIFNβ-1a (Fig. 1d). Interestingly, the
second-derivative UV spectrum of metal-catalyzed oxidized
rhIFNβ-1a was hardly affected by the addition of SDS and
differed considerably from the other spectra in all regions
(Fig. 1d). In particular, the intensities of the positive and
negative peaks in the spectrum are relatively low, suggesting
that the aromatic amino acid residues in metal-catalyzed
rhIFNβ-1a remained buried in presence of SDS.
High Performance Size Exclusion Chromatography (HP-SEC)
The elution buffer used for high performance size exclusion
chromatography (HP-SEC) contained 0.1% (w/v) SDS to
reduce the interaction of the protein with the column
material (27). Since SDS may dissociate non-covalent
protein bonds, this HP-SEC method allows us to detect
monomers and covalently bound or strongly associated
Method Parameter Untreated MCO H2O2 Guanidine
DLS Z-ave (μm) 3.2 1.6 3.9 0.35
Z-ave with SDSa(μm) 0.21 0.54 0.12 0.14
PDI 1.0 1.0 1.0 0.4
PDI with SDSa 0.5 0.7 0.5 0.5
UV OD280/OD260 1.03 0.99 0.95 0.94
OD280/OD260 with SDSa 1.58 1.02 1.89 1.85
OD350 nm 0.13 0.21 0.25 0.28
OD350 nm with SDSa 0.01 0.16 −0.01 −0.01
HP-SECb Monomer fraction (%) 71 13 61 18
Dimer fraction (%) 14 8 10 42
Oligomer fraction (%) 2 68 9 28
Unrecovered fraction (%) 13 11 20 12
RP-HPLCc “Native” fraction (%) 94 2 0 7
Oxidized fraction (%) 0 0 63 0
Aggregated fraction (%) 6 0 0 62
Unrecovered fraction (%) 0 98 37 31
Table I Overview of the Physico-
chemical Characteristics of Untreat-
ed (Untreated), Metal-Catalyzed
Oxidized (MCO), Hydrogen Perox-
ide Treated (H2O2), and Guanidine
Treated (Guanidine) rhIFNβ-1a
a 0.01% (w/v) SDS was added to the
rhIFNβ-1a preparations before
analysis.
b Fractions were calculated from the
area under the curve (AUC) for
each peak and an extinction
coefficient ðE1cm0:1%Þ rhIFNβ-1a at
λ=280 nm (32). The range of
each fraction is shown in Fig. 2
c Percentages were based on
the AUC of each peak relative to the
total AUC for untreated
rhIFNβ-1a. The different RP-HPLC
peaks are shown in Fig. 3
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non-covalent multimers of rhIFNβ-1a (Fig. 2 and Table I).
The chromatograms generally showed three different
peaks, which could be attributed to rhIFNβ-1a monomers,
dimers, and oligomers according to previous observations
(10). The oligomers eluted after the void volume but before
the dimers, thus possessing molecular weights between
45 kDa and 150 kDa, which is the column exclusion limit.
The monomer peaks were slightly tailing, probably due to
partial unfolding of the rhIFNβ-1a monomer and/or
interaction with the column material. All preparations
showed an unrecovered fraction (Table I), which may be
due to aggregates too large to enter the column or unfolded
proteins adsorbing onto the column material. Untreated
rhIFNβ-1a contained mainly monomeric protein (71%),
whereas most metal-catalyzed oxidized rhIFNβ-1a eluted as
oligomer (68%). H2O2-mediated oxidation of rhIFNβ-1a
resulted in increased percentages of oligomer (7%) and
unrecovered protein (20%) as compared with untreated
rhIFNβ-1a (2% and 13%, respectively). Guanidine-treated
rhIFNβ-1a, on the other hand, showed relatively high
percentages of dimer (42%) and oligomer (28%).
Reversed-Phase High Performance Liquid Chromatography
(RP-HPLC)
During RP-HPLC of rhIFNβ-1a an oxidized form of the
protein (presumably a methionine sulfoxide derivative) has
been reported to elute prior to the main peak, followed by
several other peaks containing oligomerized protein (25).
When applying the same method, untreated rhIFNβ-1a was
found to consist of “native” protein and a relatively low
percentage (6%) of aggregates without any detectable
oxidation (Fig. 3 and Table I). Metal-catalyzed oxidized
rhIFNβ-1a showed a very low protein recovery of 2%
compared with untreated rhIFNβ-1a, likely because a high
amount of aggregates was captured by the guard column.
About 63% of H2O2-treated rhIFNβ-1a eluted at a position
corresponding to oxidized rhIFNβ-1a, while the remaining
protein fraction was not recovered. The guanidine-treated
preparation contained some native rhIFNβ-1a (7%) and large
fractions of detectable (62%) as well as non-detectable (31%)
aggregates, but no measurable amounts of oxidized protein.
Immunogenicity
The total anti-rhIFNβ IgG titers after 3 weeks of injections
with untreated and degraded rhIFNβ-1a in wild-type mice
are shown in Fig. 4a. All samples induced antibodies, which
was expected since human interferon beta is a foreign
protein to wild-type mice (10–12). The antibodies were
measured against untreated rhIFNβ-1a. In addition to
binding antibodies (BABs), the majority of the wild-type
mice showed neutralizing antibodies (NABs) against all
products (Table II). These results imply that all prepara-
tions contained preserved epitopes present in native
rhIFNβ-1a. Figure 4b shows the IgG response of the
Fig. 1 UV spectra (a, c) and second-derivative UV spectra (b, d) in the absence (a, b) and presence (c, d) of 0.01% (w/v) SDS, of untreated (Untreated),
metal-catalyzed-oxidized (MCO), hydrogen peroxide-treated (H2O2), and guanidine-treated (Guanidine) rhIFNβ-1a.
2398 van Beers et al.
transgenic mice against the different rhIFNβ-1a prepara-
tions. The transgenic mice were immune-tolerant for
untreated rhIFNβ-1a except for two animals. Similar low
immunogenicity in transgenic mice was observed for
guanidine-treated rhIFNβ-1a. Metal-catalyzed oxidized
rhIFNβ-1a, however, was significantly more immunogenic
than the untreated product, with 100% of the mice
responding. Also, H2O2-mediated oxidation seemed to
increase the immunogenicity of untreated rhIFNβ-1a, with
eight out of nine mice responding. Hardly any transgenic
mice showed NABs at day 21 (Table II), in concordance
with previous observations (10,12).
DISCUSSION
The unwanted immunogenicity of therapeutic cytokines,
like that of other protein pharmaceuticals, is greatly
influenced by the molecular characteristics (10,20). To
investigate the effect of oxidation and aggregation on the
immunogenicity of interferon beta, four different rhIFNβ-
1a samples were prepared, characterized, and tested in
transgenic immune-tolerant mice.
The starting material, untreated rhIFNβ-1a, contained
about 70% monomer as well as dimer, oligomer, and most
likely protein that was too large to be recovered by HP-SEC.
Some large non-covalent aggregates were present, measur-
ing up to 3 μm and heterogeneous in size according to DLS.
Almost 80% of the metal-catalyzed oxidized rhIFNβ-1a
product consisted of oligomers and larger aggregates with a
relatively high degree of covalent bonds. H2O2-treated
rhIFNβ-1a showed similar diameter and polydispersity in
absence and presence of SDS as untreated rhIFNβ-1a, but
it contained about 10% less monomer according to HP-
SEC. Guanidine-treated rhIFNβ-1a mostly consisted of
dimers and oligomers, in total comprising 70% of the
sample according to HP-SEC. The larger aggregates
detected by DLS were less heterogeneous and smaller in
size (up to 0.4 μm) than those in untreated rhIFNβ-1a.
Second-derivative UV spectroscopy demonstrated changes
in the tertiary protein structure of the degraded samples
compared to the untreated product. The chromophores in
Fig. 2 Size-exclusion chromatograms of a untreated, b metal-catalyzed-
oxidized, c hydrogen-peroxide-treated, and d guanidine-treated rhIFNβ-
1a. The vertical dashed lines show the range of each peak with (1) mainly
representing the oligomer, (2) the dimer, and (3) the monomer fraction.
Fig. 3 RP-HPLC analysis of untreated (Untreated), hydrogen-peroxide-
treated (H2O2) and guanidine-treated (Guanidine) rhIFNβ-1a. The
chromatogram of metal-catalyzed-oxidized rhIFNβ-1a was not included
because hardly any peaks were detected. Peaks are labeled with (O)
representing oxidized, (N) “native,” and (A) aggregated rhIFNβ-1a.
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guanidine-treated rhIFNβ-1a showed shifts to more hydro-
phobic environments, possibly due to the degradation
procedure involving denaturation and subsequent refolding
of slightly unfolded proteins in the untreated product. Also,
the formation of additional dimers and oligomers could have
reduced the exposure of these residues to the solution. In
presence of SDS, the second-derivative UV spectrum of
metal-catalyzed oxidized rhIFNβ-1a showed remarkable
differences with the other samples, suggesting a high propor-
tion of covalent aggregates and/or chemically modified
(perhaps oxidized) chromophores.
Protein oxidation was detected in H2O2-treated
rhIFNβ-1a but not in untreated or guanidine-treated
rhIFNβ-1a. Theoretically, it is possible that the unrecov-
ered fraction (31%) in RP-HPLC of guanidine-treated
rhIFNβ-1a (Table I) contained oxidized protein. However,
it is not likely that incubation with guanidine would cause
protein oxidation. Oxidation of the highly aggregated
metal-catalyzed oxidized rhIFNβ-1a could not be assessed
with RP-HPLC using UV detection, due to low protein
recovery. For this reason, preliminary tests were per-
formed with liquid chromatography mass spectrometry
(LC-MS), demonstrating that metal-catalyzed oxidation of
rhIFNβ-1a increased the ratio of oxidized versus non-
oxidized Trp22 two-fold compared with untreated
rhIFNβ-1a (data not shown). Oxidation apparently affected
the tryptophan at position 22, which is close to the receptor
binding site and relatively exposed to the solvent (7,28). We
also have indications based on intrinsic fluorescence
(excited at 360 nm) and 4-(aminomethyl)-benzenesulfonic
acid derivative fluorescence that the metal-catalyzed
oxidized sample contained relatively high amounts of
oxidized aromatic residues. Interestingly, metal-catalyzed
oxidized rhIFNβ-1a was significantly more immunogenic
than untreated rhIFNβ-1a in transgenic mice immune
tolerant for human interferon beta. H2O2-oxidized
rhIFNβ-1a induced BABs in a high percentage of
transgenic mice (88%) compared with untreated and
guanidine-treated rhIFNβ-1a (20% and 22%, respective-
ly); however, the difference in BAB levels between these
samples was not statistically significant. Although guani-
dine-treated rhIFNβ-1a was considerably aggregated, it
showed poor immunogenicity comparable to untreated
rhIFNβ-1a in transgenic mice.
The multiple processes involved, such as aggregation,
oxidation, and change in conformation, make it difficult to
determine the contribution of each to the observed
immunogenicity. Yet we hypothesize that a particular
combination of oxidation and aggregation could be
responsible for the immune response against rhIFNβ-1a.
Likewise, oxidized and aggregated recombinant human
interferon alpha-2b (rhIFNα-2b) induced antibodies in
transgenic immune-tolerant mice, whereas protein that
was either oxidized or aggregated did not trigger an
Fig. 4 Immunogenicity of untreated, metal-catalyzed-oxidized (MCO),
hydrogen-peroxide-treated (H2O2) and guanidine-treated (Guanidine)
rhIFNβ-1a in (a) wild-type and (b) transgenic mice. Bars show BAB titers
of total IgG against rhIFNβ as determined by ELISA at day 21 for each
individual mouse injected daily, from Monday to Friday, i.p. for 3 weeks.
Non-responders were given a titer of 10. Statistical analyses (Kruskal-Wallis
non-parametric one-way ANOVA with Dunn’s multiple comparison test)
were performed comparing the titers of each treatment group with the
titers of mice injected with untreated rhIFNβ-1a. Treatment groups that
differ significantly (p<0.05) from the mice injected with untreated rhIFNβ-
1a are indicated.
Table II Number of Wild-Type and Transgenic Mice Out of the Total
Number of Mice Per Treatment Group Showing Neutralizing Antibodies
Against rhIFNβ at Day 21. Six Out of 80 Mice Died During the Study Due
to Handling or Other Reasons, Such as Liver or Heart Problems
Wildtype Transgenic
Untreated rhIFNβ-1a 7/8 0/10
Metal-catalyzed-oxidized rhIFNβ-1a 6/9 0/9
H2O2-treated rhIFNβ-1a 9/10 1/9
Guanidine-treated rhIFNβ-1a 9/10 0/9
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immune response in these mice (20). Metal-catalyzed
oxidation of rhIFNα-2b was reported to result in the
formation of methionine sulfoxides as well as covalent
aggregates. Hermeling et al. proposed that these aggregates
comprised repetitive (more than 10), optimally spaced (5–
10 nm), and native-like epitopes that could stimulate B-cells
to produce antibodies (29–31) and thereby break immune
tolerance of the transgenic mice. H2O2-treated rhIFNα-2b
also contained oxidized methionines but no detectable
aggregates, explaining the absence of antibodies against this
product in transgenic mice (20). In the present study,
aggregates were formed by H2O2-mediated oxidation of
rhIFNβ-1a, which is a protein with relatively poor solubility
and a high propensity to aggregate (6–8), as compared to
rhIFNα-2b.
The tolerance of transgenicmice for glutaraldehyde-treated
and boiled rhIFNα-2b was explained by the loss of native
epitopes according to the absence of anti-rhIFNα-2b IgG titers
in wild-typemice (20). In our study, loss of native epitopes was
most probably not the reason for the poor immunogenicity of
untreated and guanidine-treated rhIFNβ-1a, since the wild-
type mice developed anti-rhIFNβ-1a IgG and NABs.
Apparently, aggregation without oxidation is not sufficient
to trigger a robust immune response against rhIFNβ-1a in
our transgenic mouse model, as was seen for untreated and
guanidine-treated rhIFNβ-1a as well as previously studied
stressed rhIFNβ-1a (10). Oxidation of an amino acid residue
may lead to alterations in secondary and tertiary protein
structure, enhance the exposure of hydrophobic areas and
consequently result in protein aggregation (19). In general,
H2O2 or other oxidizing agents in solution induce chemical
modifications of the more solvent-exposed labile amino acid
residues, whereas trace metal ions rather cause modification
of amino acid residues in the vicinity of metal-binding sites,
such as the ionic side chains of asparagine, glutamine, and
lysine (19). Different mechanisms of oxidation and subsequent
aggregation account for differences in the characteristics of
the aggregates, such as size, covalent versus non-covalent
bonds, and degree of conformational change. Further
research is definitely needed to elucidate how oxidative
pathways lead to aggregation and how this relates to the risk
of (enhanced) immunogenicity. Strategies to prevent oxida-
tion (e.g. by adding antioxidants or chelating agents) during
processing and formulation of pharmaceutical proteins must
be based on the underlying mechanism leading to protein
modification.
CONCLUSIONS
This work shows that oxidation of rhIFNβ-1a via two
different pathways led to aggregation of the protein,
thereby increasing the risk of immunogenicity as demon-
strated in our transgenic immune-tolerant mouse model. In
contrast, two different products that were highly aggregated
but did not contain measurable levels of oxidation were
hardly immunogenic in the same mouse model. Especially
metal-catalyzed oxidation of rhIFNβ-1a may lead to the
formation of aggregates with distinct characteristics capable
of overcoming the immune tolerance for the protein.
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